Literature DB >> 8129457

Increased frequency of in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis.

P P Sfikakis1, J Tesar, S Theocharis, G L Klipple, G C Tsokos.   

Abstract

OBJECTIVE: Activated T lymphocytes are involved in the pathogenesis of scleroderma (systemic sclerosis, SSc); such cells rapidly divide in vivo and are thus theoretically subject to random mutation more frequently than resting cells. To study whether SSc is associated with rapidly expanding T cell clones the frequency was determined of in vivo mutated T cells (MF) at the hypoxanthine guanine phosphoribosyl transferase (hprt) gene in the peripheral blood from patients with SSc. Specific clinical or serological associations were also investigated.
METHODS: Peripheral blood lymphocytes from 16 healthy individuals and 20 patients with SSc were cultured using an hprt clonal assay; mutated and wild T cell clones were established to assess individual values of T cell MF. T cell clones were further expanded in vitro and their phenotype was determined by standard immunofluorescence technique. Enzyme-linked immunosorbent assays were used for simultaneous measurements of plasma levels of soluble Interleukin-2 receptors (s-IL-2R) and Intercellular adhesion molecule-1 (s-ICAM-1). RESULT: Mean (SD) value of T cell MF in patients with SSc was 2.5-fold higher than the normal mean (SD) value [10.6 (6.6) x 10(-6) v [4.4 (2.8) x 10(-6), p = 0.0007]. Eleven of 20 patients with SSc (55%) had T cell MF values greater than two SD above the normal mean value. The majority (84%) of mutated T cells had a helper/inducer, memory phenotype while 12% were cytotoxic/suppressor T cells. There was no association between T cell MF and the extent of skin involvement or the duration of Raynaud's phenomenon. High individual T cell MF values were not related to a possible concurrent immune overactivity as assessed by plasma levels of s-IL-2R and s-ICAM-1. Patients with long standing skin disease, however, had almost double T cell MF values than patients with early skin disease [(13.6 (7.4)) x 10(-6) v (7.5 (4.3)) x 10(-6), p = 0.03], suggesting that increased T cell MF in SSc may reflect an ongoing process of chronic in vivo T cell proliferation and/or prolonged survival.
CONCLUSION: Increased in vivo T cell mutation in patients with SSc suggests that excessive division and/or survival of T cell clones contribute to the pathology in SSc; this approach can be used in further investigations to identify the stimulus that is triggering T cell activation in this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129457      PMCID: PMC1005264          DOI: 10.1136/ard.53.2.122

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

1.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

2.  Detection of somatic mutations in man: evaluation of the microtitre cloning assay for T-lymphocytes.

Authors:  L Henderson; H Cole; J Cole; S E James; M Green
Journal:  Mutagenesis       Date:  1986-05       Impact factor: 3.000

3.  Use of T-cell receptor gene probes to quantify the in vivo hprt mutations in human T-lymphocytes.

Authors:  J A Nicklas; J P O'Neill; R J Albertini
Journal:  Mutat Res       Date:  1986-01       Impact factor: 2.433

4.  Refinement of a T-lymphocyte cloning assay to quantify the in vivo thioguanine-resistant mutant frequency in humans.

Authors:  J P O'Neill; M J McGinniss; J K Berman; L M Sullivan; J A Nicklas; R J Albertini
Journal:  Mutagenesis       Date:  1987-03       Impact factor: 3.000

5.  Increased proto-oncogene expression in peripheral blood T lymphocytes from patients with systemic sclerosis.

Authors:  A Kahan; J Gerfaux; A Kahan; A M Joret; C J Menkès; B Amor
Journal:  Arthritis Rheum       Date:  1989-04

6.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.

Authors:  C Taswell
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

7.  Cellular immunity to collagen and laminin in scleroderma.

Authors:  J E Huffstutter; F A DeLustro; E C LeRoy
Journal:  Arthritis Rheum       Date:  1985-07

8.  In vivo mutant frequency rises among breast cancer patients after exposure to high doses of gamma-radiation.

Authors:  K Messing; W E Bradley
Journal:  Mutat Res       Date:  1985-10       Impact factor: 2.433

9.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.

Authors:  B Freundlich; S A Jimenez
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

10.  Alterations of the hprt gene in human in vivo-derived 6-thioguanine-resistant T lymphocytes.

Authors:  R J Albertini; J P O'Neill; J A Nicklas; N H Heintz; P C Kelleher
Journal:  Nature       Date:  1985 Jul 25-31       Impact factor: 49.962

View more
  5 in total

Review 1.  Clinical use of the measurement of soluble cell adhesion molecules in patients with autoimmune rheumatic diseases.

Authors:  P P Sfikakis; G C Tsokos
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

2.  Neutrophils, nitric oxide synthase, and mutations in the mutatect murine tumor model.

Authors:  J K Sandhu; H F Privora; G Wenckebach; H C Birnboim
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

3.  Increased levels of alternatively spliced interleukin 4 (IL-4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis.

Authors:  L I Sakkas; C Tourtellotte; S Berney; A R Myers; C D Platsoucas
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 4.  Molecular characterization of hypoxanthine guanine phosphoribosyltransferase mutant T cells in human blood: The concept of surrogate selection for immunologically relevant cells.

Authors:  Noah A Kaitz; Cindy L Zuleger; Peng Yu; Michael A Newton; Richard J Albertini; Mark R Albertini
Journal:  Mutat Res Rev Mutat Res       Date:  2022-03-11       Impact factor: 7.015

5.  Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis.

Authors:  Nikolaos I Vlachogiannis; Maria Pappa; Panagiotis A Ntouros; Adrianos Nezos; Clio P Mavragani; Vassilis L Souliotis; Petros P Sfikakis
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.